PGN36
Based on 1 Customer Validation
PGN36 is a selective cannabinoid CB2 receptor (CB2R) antagonist with Kis of 0.09 µM and >40 µM for CB2R and CB1R, respectively. PGN36 abolishes the increase in collagen type I gene expression by the inducer of bone activity. PGN36 is able to cross the blood-brain barrier. PGN36 can be used for the study of frontotemporal dementia (FTD).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.38%
- CAS 番号: 1564253-75-3
- 分子式: C21H23N3O3
- 分子量:365.43
-
保管条件:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
生物活性
|
cannabinoid type-2 receptors 0.09 μM (Ki) |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Six-month-old mice received stereotaxic injections of an adeno-associated virus expressing human TAUP301L protein (AAV-TAUP301L) into the right hippocampus[2].
-
Dosage:5 mg/kg
-
Administration:i.p.; daily; for three weeks
-
Result:Effectively alleviates TAUP301L-induced cognitive decline.
Reduced TAU protein expression levels and restore synaptic plasticity.
Modulated TAUP301L-induced pyroptosis.
化学情報
-
CAS 番号 1564253-75-3
-
性状 Solid
-
分子量 365.43
-
分子式 C21H23N3O3
-
Color Light yellow to yellow
-
SMILES
O=[N+](C1=CC2=C(N(CC3=CC=CC=C3)N=C2OCC4CCCCC4)C=C1)[O-]
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
DMSO : 12.5 mg/mL (34.21 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (278 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. González-Naranjo P, et al. New cannabinoid receptor antagonists as pharmacological tool. Bioorg Med Chem. 2020 Oct 1;28(19):115672. [Content Brief]
[2]. Silva-Llanes I, et al. Targeting CB2 receptor with a novel antagonist reverses cognitive decline, neurodegeneration and pyroptosis in a TAU-dependent frontotemporal dementia mouse model. Brain Behav Immun. 2025 Mar 11;127:251-268. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7365 mL | 13.6825 mL | 27.3650 mL | 68.4126 mL |
| 5 mM | 0.5473 mL | 2.7365 mL | 5.4730 mL | 13.6825 mL | |
| 10 mM | 0.2737 mL | 1.3683 mL | 2.7365 mL | 6.8413 mL | |
| 15 mM | 0.1824 mL | 0.9122 mL | 1.8243 mL | 4.5608 mL | |
| 20 mM | 0.1368 mL | 0.6841 mL | 1.3683 mL | 3.4206 mL | |
| 25 mM | 0.1095 mL | 0.5473 mL | 1.0946 mL | 2.7365 mL | |
| 30 mM | 0.0912 mL | 0.4561 mL | 0.9122 mL | 2.2804 mL |